Anavex Life Sciences Corp (AVXL)

[Doc328]

Knowing the current and future competitive landscape is important for Biotech investing. When "Dr. Missling mentioned at the ASM that we are doing a PDD trial with similar endpoints as Lilly" do you think he meant an oncology drug?

Another possibility (maybe even 100% certainty) is that he meant LY3154207. This is a Lilly drug that just completed enrollment for PDD and has similar inclusion and exclusion criteria and the identical primary endpoint and many of the same secondary endpoints. MOA is different than A273. Lilly calls this a phase 2 but there are > 300 patients in the study. They changed the clinicaltrials.gov status to not recruiting in April so LPLV will be in July and Lilly should have results by October.